Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapy for the treatment of autoimmune diseases. Their lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T therapy currently in Phase 2b clinical development for patients with generalized myasthenia gravis (MG). They are also developing Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T therapy. Cartesian operates a wholly-owned, state-of-the-art GMP manufacturing facility in Gaithersburg, Maryland.

Cartesian's focus on mRNA-based therapies aims to create a safer and more accessible alternative to conventional DNA-based CAR-T therapies. Their approach eliminates the need for preconditioning chemotherapy, enables outpatient administration, and reduces the risk of genomic integration. By combining cutting-edge science with an integrated approach to research, development, and manufacturing, Cartesian strives to bring potentially life-changing treatments to patients with autoimmune diseases.

Cartesian Therapeutics offers a dynamic and flexible work environment, where team members learn and grow through exposure to an immersive experience. The company's highly integrated approach, with discovery, cGMP manufacturing, and clinical operations all under one roof, fosters a sense of family and cross-functional collaboration.

Cartesian Therapeutics is expanding its team of scientists dedicated to developing cutting-edge cell therapies, offering employees a highly integrated approach to biotech, with discovery, cGMP manufacturing, and clinical operations all under one roof. Team members have the opportunity to learn and grow through exposure to an immersive experience, with a sense of family stemming from close, cross-functional, and continuous conversation with highly committed colleagues. This results in a fast-paced, innovative work environment that fosters professional development and leads to potential next-generation therapies for patients.

Cartesian Therapeutics is a clinical-stage biotechnology company dedicated to developing and delivering innovative mRNA cell therapies to patients suffering from autoimmune diseases. Driven by a team of physician-scientists, Cartesian aims to pioneer potent yet safe therapies with curative potential, leveraging its proprietary RNA Armory® platform to create precision-engineered cells for diverse cell therapies. Through its pipeline of mRNA CAR-T and rMSC therapies, Cartesian is committed to expanding the reach of cell therapy to address a variety of autoimmune diseases, including myasthenia gravis and systemic lupus erythematosus, and to improve the lives of patients with these debilitating conditions.

Cartesian Therapeutics fosters a collaborative and fast-paced environment where team members are encouraged to learn and grow through exposure to an immersive experience. They prioritize close, cross-functional communication and teamwork, creating a sense of family among highly committed colleagues. This dynamic culture drives innovation and leads to the development of potentially life-changing therapies for patients.

Cartesian Therapeutics emphasizes a highly integrated approach to biotechnology, with discovery, manufacturing, and clinical operations occurring under one roof. This fosters a collaborative environment where team members from diverse backgrounds learn and grow together. They are proud members of the Gaithersburg biotech community and seek individuals who share their passion for developing next-generation cell therapies.